PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.\', \'Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.\', \'Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.\', \'Shimadzu Corporation, Kyoto, Japan.\', \'Department of Anesthesia, Kyoto University Hospital, Kyoto, Japan.\', \'Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.\', \'Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.\', \'Department of Primary Care and Emergency Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/psp4.12736
?:doi
?:hasPublicationType
?:journal
  • CPT: pharmacometrics & systems pharmacology
is ?:pmid of
?:pmid
?:pmid
  • 34793625
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34793625>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34793625>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all